Please login to the form below

Not currently logged in
Email:
Password:

Tredaptive authorised in the EU

New cholesterol-lowering drug, Tredaptive, has been given marketing authorisation for use in all 27-member countries of the European Union, as well as Iceland and Norway
New cholesterol-lowering drug, Tredaptive, has been given marketing authorisation for use in all 27-member countries of the European Union, as well as Iceland and Norway.

The Merck Sharp & Dhome (MSD) manufactured medicine has been developed for the treatment of patients with dyslipidaemia, which can be a side effect of diabetes, and raised cholesterol. It has been licensed for use in combination with statins or as a monotherapy when statins are inappropriate.

According to MSD, non-pharmacological, dietary remedies such as exercise and weight reduction should be continued while patients are being treated with the medicine.

Professor Ian Young, consultant in clinical biochemistry at Queen's University in Belfast called the new drug 'an important treatment option'.

"The approval of Tredaptive in the European Union further reinforces our long-standing commitment to the cardiovascular area by bringing novel and innovative therapies to patients," said Stefan Oschmann, president of MSD Europe, Middle East, Africa and Canada.

22nd July 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SpotMe

SpotMe is the leading technology and service provider of enterprise engagement platforms with a focus on live events, virtual and...

Latest intelligence

women
Advancing women in healthcare
Fostering the next generation of leaders...
The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....
It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...

Infographics